市場調查報告書
商品編碼
1497560
生物製造中的病毒檢測和定量市場:按產品類型、技術、應用和最終用戶分類 - 2024-2030 年全球預測Biomanufacturing Viral Detection & Quantification Market by Offering Type (Consumables, Instruments, Services), Technology (Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Plaque Assay), Application, End User - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
生物製造中的病毒檢測和定量市場規模預計到2023年為26.7億美元,到2024年達到28.9億美元,到2030年預計達到47.1億美元,複合年成長率為8.40%。
生物製藥製造市場中的病毒檢測和定量包括涉及生物製藥製造過程中病毒污染物識別和測量的技術、服務和解決方案的開發、生產和商業化的行業和部門。增加對生物製藥研究和開發的投資正在促進市場成長。在備受矚目的污染事件後,人們對產品安全的認知不斷提高,加上嚴格的監管要求的訂定,正在推動生物製造市場中病毒檢測和定量的業務成長。然而,高昂的測試成本和複雜的監管核准流程可能會對中小企業造成進入壁壘,影響市場競爭。此外,需要高技能人員執行和解釋複雜的檢測也增加了市場空間的操作挑戰。此外,新型病毒去活化方法和即時病毒檢測技術的開拓將為市場帶來創新機會。跨不同平台的檢測標準化的研究舉措為市場提供了巨大的成長潛力。
主要市場統計 | |
---|---|
基準年[2023] | 26.7億美元 |
預測年份 [2024] | 28.9億美元 |
預測年份 [2030] | 47.1億美元 |
複合年成長率(%) | 8.40% |
區域洞察
在美洲,美國和加拿大是生物製造中病毒檢測和定量的關鍵市場。這些美洲地區的特點是先進的醫療保健系統、較高的人均醫療保健成本以及嚴格的生技藥品安全性和有效性法規環境。在歐洲國家,生物製造業具有前瞻性,注重創新、品質和安全。該歐洲、中東和非洲地區的客戶熱衷於採用符合歐盟嚴格法規結構的尖端病毒檢測技術。由於醫療保健投資增加和生物製藥需求不斷成長,中東地區呈現出有希望的成長。由於消費者對本地生產和進口生技藥品品質保證的需求不斷增加,中東地區的病毒檢測和定量市場仍處於起步階段。由於強勁的經濟成長、不斷成長的醫療支出和不斷擴大的技術採用,亞太地區的生物製造領域正在經歷快速成長。亞太地區快速成長的疫苗生產產業和出口市場推動了對病毒檢測和定量解決方案的需求,客戶更喜歡經濟高效且可靠的技術。
FPNV定位矩陣
FPNV 定位矩陣對於評估生物製造市場病毒檢測和定量供應商的市場定位至關重要。此矩陣提供了對供應商的全面評估,並檢驗了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可對生物製造市場病毒檢測和定量供應商的當前狀態進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外,該分析還提供了對該領域競爭性質的寶貴見解,包括累積研究期、片段化優勢和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對生物製造市場病毒檢測和定量的當前地位進行全面評估,使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[190 Pages Report] The Biomanufacturing Viral Detection & Quantification Market size was estimated at USD 2.67 billion in 2023 and expected to reach USD 2.89 billion in 2024, at a CAGR 8.40% to reach USD 4.71 billion by 2030.
The biomanufacturing viral detection and quantification market encompasses the industries and sectors involved in developing, producing, and commercializing technologies, services, and solutions for identifying and measuring viral contaminants in the biomanufacturing process. The increased investments in biopharmaceutical R&D is contributing to the market growth. The heightened awareness of product safety following high-profile contamination cases and the introduction of stringent regulatory requirements drive the business growth in the biomanufacturing viral detection & quantification market. However, the high costs of testing and the complexity of regulatory approval processes may create barriers to entry for smaller companies, affecting market competitiveness. The need for highly skilled individuals to perform and interpret complex assays adds to market space operational challenges. Moreover, developing novel viral inactivation methods and real-time viral detection technologies creates innovative opportunities in the market. The research initiative, which is directed towards standardizing assays across different platforms, creates significant growth potential in the market.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 2.67 billion |
Estimated Year [2024] | USD 2.89 billion |
Forecast Year [2030] | USD 4.71 billion |
CAGR (%) | 8.40% |
Regional Insights
In the Americas, the United States and Canada are pivotal markets for biomanufacturing viral detection and quantification. These Americas region is characterized by advanced healthcare systems, high per capita healthcare spending, and stringent regulatory environments that govern the safety and efficacy of biologics. In the European countries, the biomanufacturing sector is advanced with a strong emphasis on innovation, quality, and safety. Customers in this EMEA region are keen on adopting state-of-the-art viral detection technologies that align with the stringent EU regulatory frameworks. The Middle East shows promising growth with increased healthcare investments and a rising demand for biopharmaceuticals. The market for viral detection and quantification in the Middle East region is nascent, with a growing consumer need for quality assurance in locally produced and imported biologics. The Asia Pacific region is experiencing surge in the biomanufacturing domain, due to robust economic growth, increasing healthcare expenditures, and growing technological adoption. The demand for viral detection and quantification solutions is driven by the burgeoning vaccine production sector and export market in the APAC region, with customers showing a preference for cost-effective yet reliable technologies.
Market Insights
The market dynamics represent an ever-changing landscape of the Biomanufacturing Viral Detection & Quantification Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Biomanufacturing Viral Detection & Quantification Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Biomanufacturing Viral Detection & Quantification Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Launch of DNAllergen Real-time PCR Kits for the Reliable Detection Of Target Allergen Sequences
Gold Standard Diagnostics has launched the DNAllergen real-time PCR kits, the latest advancement in allergen testing technology. Gold Standard Diagnostics kits have been expertly designed to elevate both the specificity and sensitivity of allergen detection, offering an exceptional value for laboratories in viral detection. [Published On: 2023-08-30]
Virax Biolabs Group Limited Introduces Avian Influenza A Virus Real-Time PCR Test Kit
Virax Biolabs Group Limited has announced a significant distribution agreement to deploy its state-of-the-art Avian Influenza A Virus real-time PCR test kit across European markets adhering to CE marking standards. This crucial differentiation tool rapidly identifies AIV infections and discerns between various subtypes, notably the pathogenic H5, H7, and H9 strains, including the emergent H5N1, directly addressing the growing surveillance needs amid the H5N1's spread in Europe. Designed for laboratory application, this kit epitomizes an essential step in preemptively screening at-risk populations and individuals in contact with affected avian populations. [Published On: 2023-03-07]
New BGI Genomics Fluorescent RT-PCR Kit Approved for COVID-19, Influenza A & B Detection in Australia
BGI Genomics announced a significant advancement in the domain of viral detection by securing entry to the Australian Register of Therapeutic Goods for its innovative Multiplex Real-time Fluorescent RT-PCR Kit. This state-of-the-art diagnostic tool markedly enhances the efficiency of biomanufacturing viral detection procedures by enabling qualitative, in vitro differentiation of SARS-CoV-2, influenza A, and influenza B viruses, via a single sampling of throat swabs. With this approval, the company aimed to expand their business presence in the Australia region. [Published On: 2023-03-05]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Biomanufacturing Viral Detection & Quantification Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Biomanufacturing Viral Detection & Quantification Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., BASF SE, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux SA, Charles River Laboratories, Danaher Corporation, Genscript Biotech Corporation, Hamilton Company, Illumina, Inc., LG Chem, Ltd., Lonza Group Ltd., Merck KGaA, New England Biolabs, Norgen Biotek Corp., Oxford Nanopore Technologies PLC, PerkinElmer, Inc., Promega Corporation, QIAGEN N.V., Recipharm AB, Sartorius AG, Shimadzu Corporation, Takara Bio Inc., Thermo Fisher Scientific Inc., Thomas Scientific LLC, and Zymo Research Corporation.
Market Segmentation & Coverage